216 related articles for article (PubMed ID: 30052269)
1. Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.
Morcos PN; Cleary Y; Sturm-Pellanda C; Guerini E; Abt M; Donzelli M; Vazvaei F; Balas B; Parrott N; Yu L
J Clin Pharmacol; 2018 Dec; 58(12):1618-1628. PubMed ID: 30052269
[TBL] [Abstract][Full Text] [Related]
2. Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.
Morcos PN; Guerini E; Parrott N; Dall G; Blotner S; Bogman K; Sturm C; Balas B; Martin-Facklam M; Phipps A
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):388-397. PubMed ID: 27545320
[TBL] [Abstract][Full Text] [Related]
3. Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment.
Alsmadi MM; Al-Daoud NM; Jaradat MM; Alzughoul SB; Abu Kwiak AD; Abu Laila SS; Abu Shameh AJ; Alhazabreh MK; Jaber SA; Abu Kassab HT
Biopharm Drug Dispos; 2021 Jun; 42(6):263-284. PubMed ID: 33904202
[TBL] [Abstract][Full Text] [Related]
4. Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
Morcos PN; Cleary Y; Guerini E; Dall G; Bogman K; De Petris L; Viteri S; Bordogna W; Yu L; Martin-Facklam M; Phipps A
Clin Pharmacol Drug Dev; 2017 May; 6(3):280-291. PubMed ID: 27545757
[TBL] [Abstract][Full Text] [Related]
5. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
Morcos PN; Yu L; Bogman K; Sato M; Katsuki H; Kawashima K; Moore DJ; Whayman M; Nieforth K; Heinig K; Guerini E; Muri D; Martin-Facklam M; Phipps A
Xenobiotica; 2017 Mar; 47(3):217-229. PubMed ID: 27180975
[TBL] [Abstract][Full Text] [Related]
6. Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessment.
Heinig K; Miya K; Kamei T; Guerini E; Fraier D; Yu L; Bansal S; Morcos PN
Bioanalysis; 2016 Jul; 8(14):1465-79. PubMed ID: 27329641
[TBL] [Abstract][Full Text] [Related]
7. Brigatinib pharmacokinetics in patients with chronic hepatic impairment.
Hanley MJ; Kerstein D; Tugnait M; Narasimhan N; Marbury TC; Venkatakrishnan K; Gupta N
Invest New Drugs; 2023 Jun; 41(3):402-410. PubMed ID: 37052729
[TBL] [Abstract][Full Text] [Related]
8. Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
Cleary Y; Gertz M; Morcos PN; Yu L; Youdim K; Phipps A; Fowler S; Parrott N
Clin Pharmacol Ther; 2018 Sep; 104(3):505-514. PubMed ID: 29226313
[TBL] [Abstract][Full Text] [Related]
9. LC-MS/MS determination of alectinib and its major human metabolite M4 in human urine: prevention of nonspecific binding.
Heinig K; Herzog D; Ferrari L; Fraier D; Miya K; Morcos PN
Bioanalysis; 2017 Mar; 9(5):459-468. PubMed ID: 28176528
[TBL] [Abstract][Full Text] [Related]
10. Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects.
Morcos PN; Parrott N; Banken L; Timpe C; Lindenberg M; Guerini E; Dall G; Bogman K; Sturm C; Zeaiter A; Martin-Facklam M; Phipps A
Clin Pharmacol Drug Dev; 2017 May; 6(3):266-279. PubMed ID: 27545871
[TBL] [Abstract][Full Text] [Related]
11. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report.
Park JE; Yoon YR; Kim CH; Lee J
Thorac Cancer; 2022 Apr; 13(8):1224-1226. PubMed ID: 35191596
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
[TBL] [Abstract][Full Text] [Related]
15. Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Hsu JC; Jaminion F; Guerini E; Balas B; Bordogna W; Morcos PN; Frey N
CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1357-1370. PubMed ID: 34547184
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
17. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
18. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects.
Flanagan S; Ong V; Marbury T; Jandourek A; Gandhi RG; Sandison T
Pharmacotherapy; 2024 Jun; 44(6):435-443. PubMed ID: 38840536
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]